Skip to main content
. 2003 Feb 18;88(4):516–520. doi: 10.1038/sj.bjc.6600754

Figure 3.

Figure 3

Survival of GBM patients in relation to hTERT status in their tumours. Patients, whose tumours expressed hTERT at low levels, survived significantly longer (19 months, median) than those patients who showed high hTERT levels in their tumours (8 months, median) or than hTERT-negative patients (8 months, median) did. Note the very similar survival period for high hTERT expressors and hTERT-negative patients.